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Abstract
Background: Escherichia coli infections are frequent in ICU patients. The increased resistance to
fluoroquinolones and amoxicillin/clavulanate of this pathogen mandates the prescription of broad-
spectrum antibiotics such as piperacillin/tazobactam (PIP-TAZ) or third generation cephalosporins
(3GC).
Methods: To assess incidence and impact on clinical outcome of infections with PIP-TAZ resistant
E. coli in ICU patients, we conducted a retrospective cohort study with infections due to PIP-TAZ
resistant (PIP-TAZ R) or to PIP-TAZ susceptible strains (PIP-TAZ S) between 1 January 2002 and
30 June 2004.
Results: Of 83 strains, 13 were PIP-TAZ R: 2 strains produced an extended-spectrum β-lactamase
(2%), 11 produced a high level penicillinase (13%). Prior amoxicillin or amoxicillin/clavulanate
prescription was reported in 7 cases (54%) of infections with PIP-TAZ R isolates and in 15 cases
(21%) of infections with PIP-TAZ S isolates (p = 0.03). Time of onset of the infection from hospital
admission was longer in case of infections with PIP-TAZ R than with PIP-TAZ S isolates (22 ± 32
vs 10 ± 21 days, p = 0.01). The overall ICU mortality rate was 38%. Mortality and length of stay in
ICU were similar in case of infections with PIP-TAZ R isolates and with PIP-TAZ S isolates.
Conclusion: Infections with PIP-TAZ R E. coli are frequent in ICU patients. No prognostic impact
of this pattern of resistance was found. Prescription of PIP-TAZ for empirical treatment of E. coli
infections in ICU however exposes to inappropriate therapy.
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Background
The development of resistance to antimicrobial agents has
been an ongoing and evolving process since antibiotics
were introduced a half-century ago. Antimicrobial-resist-
ant pathogens are becoming a prevalent cause of hospital-
acquired infections, particularly in intensive care units
(ICU) [1]. Members of the family Enterobacteriaceae are
the most frequent organisms isolated in clinical microbio-
logical laboratories. Escherichia coli is responsible of both
community and nosocomial infection. It is frequently
involved in sepsis in critically ill patients [2]. It is becom-
ing increasingly resistant to commonly used antibiotics
such as fluoroquinolones or amoxicillin-clavulanic acid
[3]. The widespread presence of resistant bacteria in ICU
has led to the common practice of using broad-spectrum
antimicrobial coverage in case of suspected gram-negative
sepsis. Piperacillin/tazobactam is an injectable antibiotic
mixture consisting of the semisynthetic antibiotic pipera-
cillin-sodium (PIP) and the betalactamase inhibitor tazo-
bactam-sodium (TAZ). PIP-TAZ antimicrobial spectrum
includes both Gram-positive cocci and Gram-negative
bacilli, especially enterobacteriaceae and Pseudomonas aer-
uginosa. Clinical use of PIP-TAZ is wide, especially in ICU.
It is notably proposed for the treatment of severe intra-
abdominal infections, febrile neutropenic patients at high
risk, late-onset ventilator-associated pneumonia [4-6].
Recent reports pointed out the increase in the prevalence
of PIP-TAZ resistant strains of E. coli isolated from clinical
relevant specimens in ICU [7,8]. Data regarding the
impact of antimicrobial-resistant pathogens on clinical
outcome demonstrated deleterious effects with higher
length of stay and mortality rate [9,10]. This impact was
demonstrated in case of infections due to various patho-
gens including E. coli. Previous studies focusing on the
impact of E. coli resistance concerned essentially ESBL-
producing strains and more recently resistance to fluoro-
quinolones [11,12]. We conducted a retrospective cohort
study to specially investigate the incidence of PIP-TAZ
resistance and its impact on clinical outcome of infections
with E. coli in critically ill patients.
Methods
Patients
The study was conducted at the Louis Mourier Teaching
Hospital ICU (Colombes, France), a 450-bed tertiary care
university hospital. The ICU is a 14-bed medical-surgical
unit. The investigation was conducted over a period of 2.5
years (1 January 2002 through 30 June 2004).
All clinical cultures demonstrating an E. coli isolate were
identified through records of the clinical microbiology
laboratory of Louis Mourier Teaching Hospital. Identifica-
tion and susceptibility testing of E. coli isolates were per-
formed by standard methods, using the API system 20E
(Bio Mérieux® SA, Marcy l'Etoile, France). The resistance
phenotype was determined by the disk diffusion method
with Mueller-Hinton agar [13]. Results were interpreted in
accordance with the recommendations of the Antibio-
gram Committee of the French Society for Microbiology
[14]. An isolate was considered to be intermediate if it
demonstrated a PIP-TAZ MIC ≥ 8 mg/L and resistant if
MIC was > 64 mg/L. For the purpose of this study, inter-
mediate and resistant to PIP-TAZ E. coli strains were
grouped together under the denomination of PIP-TAZ R
strains. Resistance to cefotaxime was used as a marker for
resistance to third generation cephalosporins (3GC). An
isolate was considered to be resistant if it demonstrated a
cefotaxime MIC ≥ 4 mg/L. We identified the strains resist-
ant to both PIP-TAZ and third generation cephalosporins
(E. coli PIP-TAZ R/3GC R) and the strains resistant only to
PIP-TAZ (E. coli PIP-TAZ R/3GC S).
After the selection of patients with E. coli isolates, medical
records of these patients were reviewed to determine
whether each patient met inclusion criteria. Only patients
whose isolates were responsible for infection (as opposed
to colonization) were included. Isolates from the same
patient with the same pattern identified in the course of
the same infectious episode were excluded. Infection was
defined as the presence of E. coli in a sterile milieu (such
as blood, cerebral fluid, pleural fluid, or ascitic fluid) and/
or clinically suspected infection (fever or hypothermia,
leukocytosis, signs of focal infection), and the identifica-
tion of E. coli in significant quantity from a clinical sam-
ple.
Infection was considered hospital-acquired if it appeared
48 hours after hospital admission and no evidence of
infection was present on admission. All other infections
were considered community acquired.
Data collection
Data were collected through review of inpatient medical
records. Data obtained included age, sex, race, the indica-
tion(s) for ICU admission, underlying clinical conditions,
presence of immunosuppression, severity of illness at ICU
admission. The underlying clinical conditions were classi-
fied according to the criteria proposed by McCabe and
Jackson in 3 categories: non fatal, ultimately fatal and rap-
idly fatal [15]. Immunosuppression was defined as a leu-
kocyte count less than 1000/mm3, recent use of systemic
corticosteroids (more than 10 mg/d of prednisone or
equivalent for over 2 weeks), underlying malignancy,
cytotoxic drugs, radiation treatment, or asplenia. The
severity of illness at the time of ICU admission was
assessed by SAPS II and Acute Organ System Failure (OSF)
scoring system [16,17]. Neurological and mental status
was stratified according to Glasgow Coma Score [18]. All
antibiotics instituted within 1 month prior to the occur-
rence of infection were taken into account.BMC Infectious Diseases 2008, 8:67 http://www.biomedcentral.com/1471-2334/8/67
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At the time of infection onset, the following data were
recorded: the number of hospital days before infection,
the number of ICU days before infection, the site of infec-
tion, the presence of bloodstream involvement, the pres-
ence of a coinfecting organism.
The following features of the treatment for each infection
were documented: the initial antimicrobial therapy, the
time between infection onset and initiation of adequate
antimicrobial therapy (defined as the prescription of at
least one molecule to which E. coli was susceptible). Our
primary outcome of interest was mortality in ICU. Sec-
ondary outcomes of interest were the length of stay in
ICU, the occurrence of sepsis-related complications (sec-
ondary septic shock, ARDS, development of MOF, super-
infection, infection relapse). Multiple organ failure
(MOF) was defined as the dysfunction of two or more of
the six evaluated organ systems accorded to Fagon et al.
definitions [19]. Acute respiratory distress syndrome
(ARDS) was defined according to usual criteria [20].
Statistical methods
Categorical variables were compared using Chi-square test
or Fisher's exact test when Chi-square was not appropri-
ate. Continuous variables were compared using Student's
t test. Differences between groups were considered to be
significant for variables yielding a p value ≤ 0.05.
Results
Demographics
A total of 83 E. coli strains responsible for an infection
were isolated during the study period. The strain was PIP-
TAZ R/3GC R in two cases. Both strains produced
extended-spectrum  β-lactamase. In these two cases the
infection was acquired in the ICU. In the other 81 cases of
E. coli infection, the strain was sensitive to third genera-
tion cephalosporins, and resistant to PIP-TAZ (PIP-TAZ R/
3GC S) in 11/81 cases. In these 11 cases, the strain pro-
duced a high-level penicillinase.
The demographic data at ICU admission for the 83
patients infected with a E. coli strain are shown in Table 1.
The mean age was 61 ± 16 years and 51% were male. Med-
ical conditions accounted for 96% of total admissions.
Infections accounted for 36% of admissions, respiratory
failures for 22%, and neurologic diagnoses for 20%. No
significant differences where observed between patients
infected with PIP-TAZ R isolates and with PIP-TAZ S iso-
lates with regard to age, gender, SAPS II, Glasgow scores,
immune status, and presence of an underlying fatal med-
ical condition. OSF score was significantly higher in case
of infection with PIP-TAZ R strains.
Infections
Data concerning the infections are summarized in Table
2. Bacteremia, isolated or linked to another site of infec-
tion were more frequent in case of infections with PIP-
TAZ R isolates (7/13 vs 9/70, p = 0.002). Other microor-
ganisms were associated with E. coli in 30 cases. The germs
more frequently isolated were Pseudomonas aeruginosa in 7
cases, Klebsiella sp in 5, Streptococcus pneumoniae in 5, and
Proteus mirabilis in 4. Prior antibiotic prescription was
reported in 8/13 (61%) infections with PIP-TAZ R isolates
and in 29/70 (41%) infections with PIP-TAZ S isolates.
Prior antibiotic regimen contained amoxicillin or amoxi-
cillin/clavulanate in 8 cases (61%) of infections with PIP-
Table 1: Patient characteristics on ICU admission *.
Characteristics PIP-TAZ R n = 13 PIP-TAZ S n = 70
Age (years) 61 ± 15 61 ± 16
Gender (Male/Female) 8/5 34/36
Indications for ICU admission
Infectious diseases 7 23
Respiratory failure 4 13
Neurological disturbances 0 17
Shock 16
Metabolic disturbances 1 5
Surgical diagnosis 0 3
Others 0 4
Underlying diseases
Anticipated death within 5 years ‡ 8 (61) 33 (47)
Immunosuppression 7 (54) 24 (34)
Severity of illnesses
SAPS II 63 ± 26 56 ± 21
Glasgow coma score 10 ± 4 10 ± 5
OSF score 2.5 ± 1.0 1.9 ± 1.1
*Data are presented as No (%) or mean ± SD
‡ Criteria proposed by McCabe and JacksonBMC Infectious Diseases 2008, 8:67 http://www.biomedcentral.com/1471-2334/8/67
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TAZ R isolates and in 15 cases (21%) of infections with
PIP-TAZ S isolates (p = 0.03). Time of onset of the infec-
tion from hospital admission was significantly longer in
case of infections with PIP-TAZ R isolates as compared
with PIP-TAZ S isolates (22 ± 32 vs 10 ± 21 days, p = 0.01).
Table 2: Infection characteristics and evolution during the ICU stay *.
characteristics PIP-TAZ R n = 13 PIP-TAZ S n = 70 p
Time of onset of the infection
From hospital admission 22 ± 32 10 ± 21 0.03
From ICU admission 7 ± 12 5 ± 10 NS
Nosocomially/community acquired 10 (77) 36 (51) NS
Locations of infection
Pneumonia 3 (27) 29 (41) NS
Urinary tract 4 (31) 24 (34) NS
Intra-abdominal 1 (9) 10 (14) NS
Isolated bacteremia 4 (31) 1 (1) 0.007
Other sites 1 (9) 6 (9) NS
Infection-related complications
Septic shock 6 (46) 23 (33) NS
ARDS 6 (46) 14 (20) NS
MOF 4 (31) 14 (20) NS
Superinfections 0 1 (1) NS
Relapses 0 2 (3) NS
Outcome
Length of stay in ICU 26 ± 33 21 ± 22 NS
Death during ICU stay 6 27 NS
* Data are presented as No (%) or mean ± SD
Initial antibiotherapy prescribed to patients infected with Escherichia coli Figure 1
Initial antibiotherapy prescribed to patients infected with Escherichia coli. A patient could receive more than one drug.BMC Infectious Diseases 2008, 8:67 http://www.biomedcentral.com/1471-2334/8/67
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Outcome
The overall ICU mortality rate was 38% (expected hospi-
tal mortality according to SAPS2 was 61.9%). Of 13
patients with PIP-TAZ R E. coli infection, 6 (46%) died,
compared with 27 (39%) of 70 patients with PIP-TAZ S E.
coli infection (p = 0.7). The length of stay in ICU of the
patients infected with PIP-TAZ R isolates was similar to
the one of the patients infected with PIP-TAZ S isolates
(26 ± 33 vs 21 ± 22 days, p = 0.7). The occurence of sepsis-
related complications was similar wathever the resistance
pattern for PIP-TAZ.
Antibiotherapy
Among the 83 patients, 77 received an antimicrobial ther-
apy. Initial empiric treatment was a monotherapy in 2
cases (15%) of PIP-TAZ R E. coli infection, and in 37 cases
(53%) of PIP-TAZ S E. coli infection (p = 0.02). The most
commonly used empirical antibiotics were cefotaxime,
amoxicillin alone or in combination with acid clavulanic,
fluoroquinolones, and aminoglycosides (Figure 1).
Aminoglycosides were always used in combination. Piper-
acillin/tazobactam was prescribed in only 3 cases. The
proportion of patients receiving adequate antimicrobial
therapy within 24 hours and 48 hours after diagnosis was
similar whatever the resistance pattern of E. coli for PIP-
TAZ (Figure 2).
Discussion
In our retrospective cohort of ICU patients, 16% of the
strains of E. coli isolated from clinically relevant speci-
mens were resistant or intermediate to PIP-TAZ. This is far
more than the rates observed by the French National
Observatory for Epidemiology of Bacterial Resistance to
Antimicrobials (ONERBA) that reports a 4% rate of PIP-
TAZ intermediate or resistant strains among the strains of
E. coli isolated in hospitalised patients [21]. In ICU, the
PIP-TAZ resistance rate of E. coli is much higher. Our
results confirmed those reported by Mohammedi et al.
who noted an increase in the isolation rate of E. coli inter-
mediate or resistant to PIP-TAZ in ICU patients from 6%
in 1995 to 17% in 1999 [7]. But Mohammedi et al. did
not characterise the mechanisms of resistance to PIP-TAZ.
In our cohort, two among 13 PIP-TAZ resistant strains
produced extended-spectrum β-lactamase. The produc-
tion of high-level penicillinase was the predominant
mechanism of resistance, identified in 11/13 PIP-TAZ
Percentages of patients infected with PIP-TAZ R isolates or with PIP-TAZ S isolates who were receiving appropriate antibiotic  therapy (defined as at least 1 agent to which the infecting organism was susceptible) ≤ 24 h and ≤ 48 h after samples were  obtained for culture Figure 2
Percentages of patients infected with PIP-TAZ R isolates or with PIP-TAZ S isolates who were receiving appropriate antibiotic 
therapy (defined as at least 1 agent to which the infecting organism was susceptible) ≤ 24 h and ≤ 48 h after samples were 
obtained for culture.BMC Infectious Diseases 2008, 8:67 http://www.biomedcentral.com/1471-2334/8/67
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resistant strains. This may have important consequences
for the empirical choice of antimicrobial agents: these
strains retained susceptibility to cefotaxime. The 2% (2/
83) prevalence of ESBL strains in our cohort was similar to
the prevalence recently described in French hospitals [22].
Recently, several studies revealed emergence of new ESBL-
producing E. coli especially within the community, the
CTX-M-producing isolates [23]. A limitation of our study
is that underlying mechanisms of resistance were deter-
mined only using interpretative reading of the antibio-
gram. We did not performe any molecular study to
identified the different β-lactamases.
In our cohort, a prolonged hospital stay prior to the diag-
nosis of E. coli infection or a recent antibiotic therapy con-
taining amoxicillin or amoxicillin-acid clavulanic
favoured infections with a PIP-TAZ resistant strain of E.
coli. Mohammedi et al. conducted a multivariate analysis
and identified prior use of amoxicillin and amoxicillin-
acid clavulanic as a major risk factor of infection with PIP-
TAZ resistant or intermediate strains of E. coli [8]. Their
results were in accordance with previously published data
establishing a link between prior antibiotherapy and
infection with penicillin resistant strains [24,25]. In our
study, as in any observational study, the missing data
could have reduce the strength of our observations. The
potential for unmeasured confounding data must be rec-
ognized.
In our cohort, we did not find any impact of the PIP-TAZ
resistance phenotype on the prognosis of infections with
E. coli. Several previous studies demonstrated that some
patterns of resistance were significantly associated with
mortality of E. coli infections [11,12]. Our study is the first
analyzing the association of PIP-TAZ resistance with the
outcome of E. coli infections. One explanation to the
absence of prognosis impact of PIP-TAZ resistance in our
cohort is that PIP-TAZ resistance did not result in a
decrease of the proportion of adequate initial antimicro-
bial therapy. Monocentric nature of our study could
explain this result, since PIP-TAZ was only rarely pre-
scribed empirically in our ICU. In our cohort, predomi-
nance of medical admissions leading to a low proportion
of intra-abdominal infections could have contributed to
reduced prescription of PIP-TAZ. Urinary tract infections
and pneumonia were the most frequent reported infec-
tions in our patients. PIP-TAZ is recommended for severe
community-acquired intra-abdominal infections and for
health care-associated intra-abdominal infections [4].
But, in case of pneumonia, it is recommended only for
hospital-acquired pneumonia, ventilator-associated
pneumonia, and health care-associated pneumonia in
patients with late-onset disease or risk factors for multid-
rug-resistant pathogens [6]. Third generation cepha-
losporins are the reference treatment for complicated
community-acquired urinary tract infections and is rec-
ommended for nosocomial urinary tract infections
[26,27]. Another explanation to the absence of prognosis
impact of PIP-TAZ resistance in our cohort is that our
study was likely under powered to demonstrate a clini-
cally important difference.
Our findings could have an impact on the choice of the
empirical antibiotic prescription in case of Gram negative
bacilli infection in critically ill patients. The selection of
appropriate initial antibiotic therapy remains a challenge
for the physician, who must balance the need for eradica-
tion of infection against the selection of resistant patho-
gens. The prognostic importance of appropriate initial
antimicrobial therapy both in timing and efficacy on the
causal micro-organism(s) has been underlined in many
studies [28,29]. Prescription of PIP-TAZ in case of Gram
negative bacilli infection in ICU is justified by its ability to
treat both infections with enterobacteriaceae and with
non-fermentative Gram-negative bacilli such as Pseu-
domonas aeruginosa, which are particularly frequent in ICU
patients. The SOAP study conducted in European inten-
sive care units revealed that the most common organisms
isolated in the course of sepsis were Staphylococcus aureus
(30%),  Pseudomonas species (14%), and Escherichia coli
(13%). The broad spectrum of activity of PIP-TAZ led
some authors to consider it as the standard therapy for
many infections such as ventilator-associated pneumonia
and abdominal infections [30,31]. The high isolation rate
of  E. coli intermediate or resistant to PIP-TAZ that we
report in ICU patients exposes to failure of empirical treat-
ment with PIP-TAZ. Nevertheless our study does not allow
to draw firm conclusions on the best empirical antibiotic
therapy in case of E. coli infections in ICU. Finally, it high-
lights the importance of the local surveillance of the epi-
demiology of microorganisms in devising antibiotic
strategies in a specific ICU.
Conclusion
Our results indicate that infections with PIP-TAZ R E. coli
are frequent in ICU patients. The PIP-TAZ resistance
among E. coli strains is mainly due to production of high-
level penicillinase. Prior use of amoxicillin may be a risk
factor for PIP-TAZ R E. coli open to medical intervention.
No prognostic impact of this pattern of resistance was
found in our cohort. But, large prescription of PIP-TAZ for
empirical initial antibiotic treatment of Gram negative
bacilli infections in ICU may expose to inappropriate
therapy and treatment failure.
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